NEW YORK, July 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016 financial results prior to the NASDAQ market open on Thursday, August 4, 2016. Intercept management will conduct a conference call and audio webcast on Thursday, August 4, 2016 at 8:30 a.m. Eastern Time to discuss these results.
Intercept management will also be presenting at the following investor conference:
- 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 3:40 p.m. Eastern Time
Webcast information for these events will be available on Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada. For more information about Intercept, please visit: www.interceptpharma.com.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 firstname.lastname@example.org Media inquiries: email@example.com Investor inquiries: firstname.lastname@example.org
Source:Intercept Pharmaceuticals, Inc.